This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
2024 Leads Pharma 
Fierce Pharma
OCTOBER 29, 2024
Modified dosing regimen of Eli Lilly's Alzheimer's drug leads to significant reduction in brain swelling kdunleavy Tue, 10/29/2024 - 15:25
240 240 
Fierce Pharma
JANUARY 3, 2024
Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales.
284 This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JANUARY 10, 2024
With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. Morgan Healthcare Conference.
269 
Fierce Pharma
AUGUST 22, 2024
The momentum the biopharma industry showed in the first quarter of 2024 continued into the second quarter as 21 of the industry's top 25 companies achieved year-over-year revenue increases.
243 
Pharma Marketing Network
DECEMBER 6, 2023
Reuters Events: Pharma USA 2024 is where senior pharma executives from Commercial, Marketing, Medical Affairs, RWE, Market Access, Patient Engagement, as well as key stakeholders, will come together to map out how they can deliver value to overcome the challenges that are hindering scientific innovation.
52 
Fierce Pharma
APRIL 10, 2024
Leading AstraZeneca investor defends CEO pay ahead of shareholder vote: FT zbecker Wed, 04/10/2024 - 10:49
144 144 
Pharma Marketing Network
JUNE 18, 2024
Show that pharma is driven by more than profit – to build a world that empowers all patients and leaves no one in the dark. Welcome to Pharma & Patient USA, the co-created event for patient champions in pharma, who won’t sit back. THIS is the real value of your work. Are you ready to be the new beacon of trust?
52 
European Pharmaceutical Review
AUGUST 15, 2023
CPHI, the global pharmaceutical event that spans the entire supply chain from ingredients and finished dosages to machinery, bio, and packaging will return to Fiera Milano (Rho) in 2024. We are delighted to be returning to Fiera Milano, as Italy and the Lombardy region are widely known as one of the key pharma manufacturing centres in Europe.
MedCity News
DECEMBER 5, 2023
Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.
112 
PM360
JUNE 23, 2023
Press Release Contact: Kayla Walsh Awards Coordinator, PM360 646-300-8114 kayla.walsh@pm360online.com PM360 Now Accepting Entries for 2024 Pharma Choice Awards Call for the Best Healthcare Creative from the Past Year NEW YORK, NY, June 22, 2023 : The 2024 PM360 Pharma Choice Awards are officially open for entries.
52 
eMediWrite
DECEMBER 22, 2023
Every year, pharma marketing teams engage in multi-phased, cross-functional, multi-organizational strategic planning and also in aligning work-stream dubbed “Brand Planning” by many in the industry. From a general perspective, despite large gains in site traffic (+16%), pharma website engagement rates were down.
52 
European Pharmaceutical Review
OCTOBER 8, 2024
CPHI Milan, the premier international pharmaceutical event, will be held from 8 to 10 October 2024 at Fiera Milano, Italy. Conference agenda highlights CPHI Milan will present a comprehensive conference agenda on topics such as sustainability and pharma, next generation mRNA vaccines, European regulation, biomanufacturing, and more.
52 
PM360
OCTOBER 9, 2024
London, (October 9, 2024) – As healthcare professionals (HCPs) become increasingly immune to traditional outreach strategies, the need to innovate and create meaningful customer experiences has never been more critical. Register now to secure your spot and be part of the transformation in pharmaceutical customer engagement.
52 
Pharmaceutical Technology
MAY 2, 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry involving companies developing drugs showed a 20% increase in total deal volume in the first quarter (Q1) of 2024 compared to Q1 2023, according to leading data and analytics company GlobalData’s Pharma Intelligence Center Deals Database.
52 
PM360
FEBRUARY 23, 2024
TEAM MEMBERS: Katrina Gary Senior Director of Patient Marketing Alyson McNamara Associate Director of Patient Marketing Dan Pedersen Director Andrew Prahin Creative Director Sam Hoar Lead Copywriter Parker Gibson Lead Art Director Marisa Gurovski Account Lead OTHER BROTHER TEAM MEMBERS: Stuart Bury Executive Creative Director, Other Brother Isaiah (..)
52 
PM360
OCTOBER 8, 2024
The high-profile appointment follows the merger of Bioclinica DSS, MyMeds&Me and Commonwealth Informatics under the Qinecsa brand two years ago, and the recent addition of Insife to the group in Q1 2024. It was a great honor to be approached to lead Qinecsa’s next important growth phase.
52 
PM360
FEBRUARY 22, 2024
VERYWELL HEALTH TEAM MEMBERS: Emma Brink Senior Editor Nicole Kwan Senior Editorial Director Sara Michael Group General Manager and Senior Vice President, Health Group Olivia Hunter Visual Editor Sahara Borja Visuals Manager, Health Group Dylan Wolter Senior Product Manager, Product Todd Bernard Design Lead, Product Hannah Hashmi Associate Director, (..)
52 
PM360
AUGUST 12, 2024
CineHealth brings discussion about content and storytelling from key industry thought leaders to leading healthcare conference. Veteran CINEHEALTH judge and General Hospital actor Maurice Benard will be keynoting Digital Pharma East. It is organized by the Fierce Pharma editorial and conference teams at Fierce Pharma, part of Questex.
59 
Fierce Pharma
MARCH 28, 2024
[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity | Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides
144 
Authentic Influence Group
SEPTEMBER 16, 2024
The Silent Edge: How Body Language and Communication Skills Shape Leadership Success October 9, 2024 | 8:00 AM | NYC Free Event | Limited to 30 Seats Enjoy a Breakfast Bagel | Take in the NYC Skyline | Master Leadership Through Body Language Harness the power of what’s not being said. Extraversion: Lead confidently in any setting.
130 
European Pharmaceutical Review
JUNE 4, 2024
Meeting the Divisions at ACHEMA 2024 IMA Active The ideal partner for each solid dose processing phase: granulation, tableting, capsule filling and banding, weight checking, coating, handling and washing. The GIANT5-A96 integrated blister and cartoning line redefines the parameters of flexibility, speed and compactness.
Pharmaceutical Representative Training
OCTOBER 9, 2024
3 By actively listening to providers and addressing their objections with tailored solutions, sales professionals can cultivate strong relationships that lead to success in this competitive field. Secondly, budget constraints are also a common objection in pharma sales. 2024, August 27). 2024, September 20). SBI Growth.
52 
PM360
FEBRUARY 8, 2024
THE ELEVATE HEALTHCARE MEMBERS: Scott Harper VP, Client Engagement Matt Parastino Assistant Manager, Client Engagement Tara Powers VP Creative Director, Art Sarah Ward Art Group Supervisor Carolyn Ignomirello Creative Director, Copy Tina Wack Copy Supervisor Derick Sumrall Practice Lead, Customer Experience LIVANOVA USA, INC.
52 
Clarivate
APRIL 18, 2024
In 2024, watch as the global trendsetter brings to bear its technological expertise combined with a captive Prime membership, brand recognition, and national employer buy-in to re-envision healthcare that truly works around the patient. Healthcare segment) across the nation as part of a $1 billion cost-cutting strategy.
52 
PM360
FEBRUARY 8, 2024
BIOLUMINA TEAM MEMBERS: Olivia Brooman VP, Group Account Supervisor Aine McCarthy Group Account Supervisor Jason Davis SVP, Creative Director, Art John Lee Group Art Supervisor Erika Fad VP, Group Copy Supervisor Eric Niederman VP, Group Copy Supervisor Victoria Sperling Associate Editorial Director DayVaughn McKnight Editor Kelly Davila Senior Project (..)
52 
pharmaphorum
JANUARY 9, 2023
is to acquire the 2015-established Amryt Pharma Plc. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. on 6 th January.
85 
PM360
NOVEMBER 12, 2023
Pharma brands are increasingly humanizing the patient journey today unlike ever before. The growing emphasis on more strategically aligning doctor data with patient advertising targeting is leading to better and more impactful experiences that more deeply consider the “why” behind how people approach their health.
52 
Eversana Intouch
SEPTEMBER 27, 2024
With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and numerous malignancies. And I am on site at ESMO 2024 in sunny Barcelona. Anne Marie, any insights into the unique trends at ESMO 2024?
59 
Pharmaceutical Technology
MARCH 30, 2023
The US FDA has revealed its detailed budget proposal for FY2024, which would require pharma companies to name their active pharmaceutical ingredient (API) suppliers, restart President Biden’s Cancer Moonshot, inject cash into amyotrophic lateral sclerosis (ALS) research, and enforce stricter rules around manufacturing, recalls, and shortages.
European Pharmaceutical Review
SEPTEMBER 21, 2023
“A Grand Bargain is both achievable and in everyone’s interest to overcome the collective actions problems inherent in dealing with market failures in the antimicrobial market,” stated Anthony McDonnell, lead author of the report and a senior policy analyst at the CGD.
111 
MedCity News
JULY 10, 2023
A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024. Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer.
80 
PM360
MAY 23, 2024
Enter Mike Edwards, who leads the SCEMBLIX brand team at Novartis. First, his team and agency arranged an Innovation Day, where various vendors outside the pharma space showcased innovations and technology that aimed to challenge conventional thinking. Mike’s efforts have brought dividends throughout the course of the past year.
52 
PM360
SEPTEMBER 30, 2024
Sustainable Tech’s Positive Effect on Pharma Funding Recent innovations, including rapid advancements in AI-powered technologies and GLP-1s, have significantly impacted the investment climate and consolidated funding to a smaller number of organizations in the last eight months.
European Pharmaceutical Review
NOVEMBER 21, 2023
Phase III trials of a low carbon version of GSK’s metered dose inhaler, Ventolin (salbutamol), using a next generation, lower carbon propellant, are set to start in 2024. The pharma company stated that if successful, it has the potential to reduce greenhouse gas emissions from use of the inhaler by approximately 90 percent.
116 
Medico Reach
FEBRUARY 8, 2023
The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. billion during 2020-2024. Are you intrigued to know what technologies will rule the pharma market and how they can benefit your business in 2023? from 2022 to 2030, the pharma industry will reach USD 9,241.34
52 
Pharmaceutical Technology
MAY 23, 2023
Generic and biosimilar firms are likely to heavily utilise this provision, and earlier market entry may lead to faster price drops for branded drugs. The resulting upheaval in launch strategies may mean that pharma can no longer depend on prioritising market launches in countries that support higher prices.
52 
PM360
SEPTEMBER 30, 2024
In her expanded role, Walsh will oversee agency operations, marketing and communications, and innovation for North America, while continuing to lead the PR, Influence and Social business. BridgeBio Pharma, Inc. Exagen This leading provider of autoimmune testing solutions announced the appointment of Jeffrey G.
52 
European Pharmaceutical Review
APRIL 15, 2024
Positive data from MaaT Pharma’s Microbiome Ecosystem Therapy TM (MET) MaaT013 as a treatment for acute graft-versus-host disease (aGvHD), is set to be presented at the 2024 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting. This data summary is based on an abstract from the Annual Meeting.
98 
MedCity News
APRIL 20, 2023
A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024. Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer.
103 
European Pharmaceutical Review
JUNE 7, 2024
Potential of survodutide Results presented at European Association for the Study of the Liver Congress (EASL) 2024 revealed that after 48 weeks of treatment: Actual treatment results revealed up to 87.0 percent of adults achieved at least a 30 percent relative reduction in liver fat. This was compared to 19.7 percent for those given placebo.
111 
PM360
JUNE 24, 2024
Every summer for nearly two decades EVERSANA INTOUCH experts support their clients through an annual brand planning process, and while each client is unique, similar best practices began to emerge, leading to the advent of a brand new idea. More than 100 clients attended the April 25th event both in-person and virtually.
64 
Clarivate
SEPTEMBER 11, 2024
Though there is no cure for the disease, people with Alzheimer’s can receive personalized, multimodal care and support to delay deterioration of their functional status and quality of life and alleviate the burden imposed on their care partners (Emblad, 2021; Bayly, 2021; Xiang, 2024). Food and Drug Administration, 2023 and 2024).
European Pharmaceutical Review
FEBRUARY 14, 2024
Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). ” The transaction is expected to close during the first quarter of 2024, subject to certain customary closing conditions. This is based on data from the Phase III RESPONSE trial.
European Pharmaceutical Review
DECEMBER 5, 2023
billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Carmot Therapeutics’ lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes.
110
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content